Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 11 of the 19 sources its claims cite were checked for support.

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Open access

Abstract

BACKGROUND: The SELECT trial found semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with cardiovascular disease but without diabetes. We report a prespecified analysis of the SELECT trial on the relationships between baseline adiposity measures, treatment-induced adiposity changes, and subsequent MACE risk. METHODS: were enrolled in 41 countries (804 sites) and randomised 1:1 to once-weekly semaglutide 2·4 mg or placebo. The primary outcome was time to first MACE (composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke). Adiposity measures included weight and waist circumference. In this analysis, risk of MACE occurring after 20 weeks was assessed between patients by adiposity changes in the first 20 weeks and, in a separate analysis, all in-trial MACE were assessed between patients by adiposity changes over 104 weeks. This trial is registered with ClinicalTrials.gov, NCT03574597. FINDINGS: Semaglutide significantly reduced MACE incidence compared with placebo among 17 604 patients enrolled in SELECT, with consistent benefits across all baseline weight and waist circumference categories. In the semaglutide group, analyses for linear trends showed lower baseline bodyweight and waist circumference were associated with lower incidence of MACE-an average 4% reduction in risk per 5 kg lower bodyweight (hazard ratio [HR] 0·96 [95% CI 0·94-0·99]; p=0·001) and per 5 cm smaller waist circumference (0·96 [0·93-0·99]; p=0·004). In the placebo group, lower baseline waist circumference (0·96 [0·94-0·99]; p=0·007), but not bodyweight (0·99 [0·97-1·01]; p=0·28), was associated with a lower MACE risk and weight loss was paradoxically associated with increased MACE risk. In those receiving semaglutide there was no linear trend linking weight loss at week 20 to subsequent MACE risk, but greater waist circumference reduction at week 20 was associated with lower subsequent MACE risk, and waist circumference reduction by week 104 was associated with lower in-trial risk of MACE. An estimated 33% of the observed benefit on MACE was mediated through waist circumference reduction (HR 0·86 [95% CI 0·77-0·97] after adjustment for time-varying changes in waist circumference). INTERPRETATION: The cardioprotective effects of semaglutide were independent of baseline adiposity and weight loss and had only a small association with waist circumference, suggesting some mechanisms for benefit beyond adiposity reduction. FUNDING: Novo Nordisk.

Overview

CoChat Summary

## TL;DR

This prespecified analysis of SELECT found that semaglutide’s cardiovascular benefit was consistent across baseline adiposity levels and was not explained by early weight loss. Waist circumference change was more closely related to MACE than bodyweight change, but accounted for only about 33% of the treatment benefit.

## Key findings

  • In SELECT, semaglutide reduced MACE in 17,604 patients with overweight/obesity and established cardiovascular disease without diabetes, with benefits consistent across baseline weight and waist circumference categories.
  • Among semaglutide-treated patients, lower baseline bodyweight and waist circumference were associated with lower MACE risk: about 4% lower risk per 5 kg lower bodyweight (HR 0.96, 95% CI 0.94–0.99; p=0.001) and 4% lower risk per 5 cm smaller waist circumference (HR 0.96, 95% CI 0.93–0.99; p=0.004).
  • In the placebo group, lower baseline waist circumference—but not bodyweight—was associated with lower MACE risk (HR 0.96, 95% CI 0.94–0.99; p=0.007), and weight loss was paradoxically associated with higher MACE risk.
  • Early weight loss at week 20 did not predict later cardiovascular benefit in the semaglutide group, whereas greater waist circumference reduction did; waist circumference reduction was estimated to mediate or mark 33% of semaglutide’s MACE benefit (HR 0.86, 95% CI 0.77–0.97 after adjustment for time-varying waist circumference).

## Methods

  • Prespecified analysis of the SELECT randomized, double-blind, multicentre, placebo-controlled phase 3 trial conducted in 41 countries (804 sites); participants were aged ≥45 years, had BMI ≥27 kg/m², established atherosclerotic cardiovascular disease, and no diabetes.
  • Participants were randomized 1:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo; bodyweight and waist circumference were repeatedly measured during follow-up.
  • Primary analysis evaluated time-to-first MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) using Cox models, including landmark analyses at 20 weeks and an in-trial analysis through 104 weeks; missing data were multiply imputed under missing-at-random assumptions.

## Limitations

  • The authors state that, although the trial was conducted in 41 countries, the population was predominantly White and male, which may limit generalisability.
  • The authors state that analyses of MACE by post-randomisation changes in weight or waist circumference are subject to confounding and cannot prove causation or define mechanisms.
  • The authors note that the week-20 analyses did not use the earliest observed differences in MACE between treatment groups, and the week-104 cumulative-change analyses cannot account for the timing of changes in adiposity relative to MACE.
  • Evident from the text: the study relied on waist circumference and bodyweight rather than direct body-composition measures, and the authors note future studies should include formal measures of body composition.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(25)01375-3

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

9 Valid · 1 Not valid · 7 Not checked · 68 Own results and interpretations

45 more claims

Create a free account to see all 85 claims and to verify the 4 references still open.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 24

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 143

Metadata

Authors
Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., Stensen, S., Weeke, P. E., Jeppesen, O. K., Bravo, R., Wu, C.-C., Komuro, I., Santini, F., Hjelmesæth, J., Urina-Triana, M., Buscemi, S., & Ryan, D. H.
Affiliations
  • University College London (GB)
  • Cleveland Clinic (US)
  • University of Washington (US)
  • The University of Texas Southwestern Medical Center (US)
  • Brigham and Women's Hospital (US)
  • Northwestern University (US)
  • Institute of Genetics and Cancer (GB)
  • Novo Nordisk (Denmark) (DK)
  • National Taiwan University Hospital (TW)
  • International University of Health and Welfare (JP)
  • Azienda Ospedaliera Universitaria Pisana (IT)
  • Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
  • Pennington Biomedical Research Center (US)
Corresponding author
Deanfield, John
Venue
The Lancet
Publisher
Elsevier BV
Published
2025-11
Volume
406
Issue
10516
Pages
2257-2268
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4415447839
Cited by
143
References
24
Citations by year
2026: 137 · 2025: 6
FWCI
96.79
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
semaglutide, major adverse cardiovascular events, adiposity, waist circumference, body weight, obesity, overweight, GLP-1 receptor agonists, SELECT trial, cardiovascular risk stratification
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Male, Middle Aged, Obesity, Body Mass Index, Treatment Outcome, Adiposity, Overweight, Glucagon-Like Peptide 1, Waist Circumference

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. https://app.cochat.ai/papers/10.1016/s0140-6736(25)01375-3
The paper
Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., Stensen, S., Weeke, P. E., Jeppesen, O. K., Bravo, R., Wu, C.-C., Komuro, I., Santini, F., Hjelmesæth, J., Urina-Triana, M., . . . Ryan, D. H. (2025). Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. The Lancet. https://doi.org/10.1016/s0140-6736(25)01375-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.